Sep. 8 at 3:39 PM
$ELTP
🐂 Bull case
The business is now profitable at scale. FY2026 revenue was
$148.9M, up 77%, and operating income was
$49.1M, up 151%. SSEC+1
Generic Vyvanse/lisdexamfetamine proved the commercial model. It was a major contributor to FY2026 results after its launch. SSEC
Strong cash generation. At June 30, 2026, Elite had about
$38.9M cash, versus
$29.8M at March 31. Q1 operating cash flow was about
$10.1M. SSEC
There is room to add products. Elite has been expanding its generic portfolio rather than relying entirely on one drug.
The company doesn't currently need the classic “biotech lottery ticket” outcome. It's already generating substantial revenue and profits from commercial products.